Brief: Corvus Pharmaceuticals Q2 EPS USD -0.1

Corvus Pharmaceuticals

07/08/2025 21:01

Overview

Corvus Q2 net loss widens to $8.0 mln from $4.3 mln a year ago

Company raised $35.7 mln from stock warrants, boosting cash reserves to $74.4 mln

Advancing soquelitinib in trials for atopic dermatitis and T cell lymphoma

Outlook

Company to report data from Phase 1 trial extension cohort 4 in Q4 2025

Phase 2 trial for soquelitinib in atopic dermatitis to start before year-end

Angel Pharmaceuticals to initiate Phase 1b/2 trial in China for soquelitinib

Enrollment continues in Phase 3 trial for PTCL and Phase 2 trial for ALPS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.1
Q2 Net Income
-$8 mln
Q2 Basic EPS
-$0.1
Q2 Operating Expenses
$10.26 mln
Q2 Operating Income
-$10.26 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00, about 67.9% above its August 6 closing price of $4.17

Press Release: ID:nGNX5Ql7Yj

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)